Replies to post #150809 on Biotech Values

[DewDiligence]

FoB collaboration between two companies I’d never heard of:

http://www.marketwatch.com/story/catalent-and-umn-pharma-announce-collaboration-for-biosimilar-development-and-production-in-japan-2012-12-13

Catalent Pharma Solutions and UMN Pharma Inc. today announced the signing of an agreement to provide UMN Pharma a broad range of biosimilar cell lines using Catalent's proprietary GPEx(R) technology. The development and manufacturing programs will benefit from the GPEx technology producing very stable and high yielding cell lines. [Does any company ever talk about having *low*-yielding cell lines?]

Under the agreement, UMN Pharma and its subsidiary UNIGEN, which is a contract manufacturer, will produce a number of biosimilars using Catalent's GPEx cell lines. UMN Pharma, separately, will build an alliance of pharmaceutical companies for product development including clinical trials, marketing and sales. UMN Pharma plans to begin multiple biosimilar projects with their alliance companies for the Asian market on an ongoing basis.

[DewDiligence]

Major FoB Collaborations

[New detail for ACT (f/k/a WPI)-AMGN collaboration;
new table entry for Catalent-UMN collaboration.]

 
                 Date   Targets   iHub References 
 Catalent-UMN   12/12   Asia      #msg-82556713 
 Merck KGaA-RDY  6/12   oncology  #msg-76359649 
 Daiichi-Coherus 5/12   *         #msg-75397629 
 Fujifilm-Kyowa  3/12   Humira    #msg-73800486 
 ACT-Bioton      2/12   insulin   #msg-74987123 
 ACT-AMGN       12/11   †oncology #msg-83846381, #msg-70101928 
 BAX-MNTA       12/11   various   #msg-70212854, #msg-70258421 
 Samsung-BIIB   12/11   various   #msg-69629103, #msg-80622249 
 MRK-Hanwha      6/11   Enbrel    #msg-64164954, #msg-64193403  
 MYL-Biocon      6/09   various   #msg-39119393, #msg-72421544  
 TEVA-Lonza      1/09   various   #msg-34930012, #msg-80236315 
  
 *Enbrel and Rituxan in selected Asian countries. 
  
 †Heceptin, Avastin, Rituxan, Erbitux.